The first patients have now enrolled in AIRWISE, the world’s largest ever pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to study how commonly prescribed medicines may reduce the occurrence of exacerbations of COPD.
A DNA-based Zika vaccine, dubbed GLS-5700, developed by a consortium led by Inovio Pharmaceuticals and GeneOne Life Science succeeded in a phase 1 clinical trial by producing anti-Zika response in humans.
UK-based Motif Bio reported that its skin disorder drug iclaprim has succeeded in a second phase 3 trial in patients with acute bacterial skin and skin structure infections (ABSSSI).
NHS patients are taking part in a world-first trial for a universal flu vaccine supported by the National Institute for Health Research (NIHR) and delivered by the University of Oxford in Berkshire and Oxfordshire.
Ablynx's blood disease drug caplacizumab succeeded in a phase 3 trial in patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare autoimmune blood clotting disorder.
Tricida announced that the first subject was enrolled in TRCA-301, a phase 3 study evaluating TRC101 in chronic kidney disease (CKD) patients with metabolic acidosis.
The University of Texas MD Anderson Cancer Center and Pfizer have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies.
US pharma giant Pfizer has spun off four investigational drugs into a new medicines company, dubbed SpringWorks Therapeutics.
Eleven Biotherapeutics announced that it has completed the manufacturing of all Vicinium necessary for its ongoing Phase 3 registration trial in patients with non-muscle invasive bladder cancer (NMIBC), and for its cooperative research and development agreement (CRADA) with the National Cancer Institute.
AstraZeneca has announced full results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type-2 diabetes (T2D) at a wide range of CV risk.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.